Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
IVA
$6.79
$
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.
Next Earnings
2026-02-25
Beta
0.887
Average Volume
Market Cap
Last Dividend
CIK
0001756594
ISIN
US46124U1079
CUSIP
46124U107
CEO
Andrew Obenshain
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
114
IPO Date
2020-07-10
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of “Buy” from Analysts | Shares of Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) have earned an average recommendation of "Buy" from the ten research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and two have assigned a strong buy | Defense World | 2026-02-18 02:08:56 |
| Inventiva reports preliminary 2025¹ fiscal year financial results | Daix (France), New York City (New York, United States) , February 17, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported its certain preliminary unaudited financial results for the full year ending December 31, 2025, including cash, cash equivalents, and revenues. | GlobeNewsWire | 2026-02-17 02:30:00 |
| Comparing Vera Therapeutics (NASDAQ:VERA) & Inventiva (NASDAQ:IVA) | Inventiva (NASDAQ: IVA - Get Free Report) and Vera Therapeutics (NASDAQ: VERA - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current ratings | Defense World | 2026-02-05 01:18:57 |
| Inventiva to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 | Daix (France), New York (United States), February 4, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced that CEO Andrew Obenshain has been invited to participate in a fireside chat at the upcoming Guggenheim Emerging Outlook: Biotech Summit 2026. The conference is being held February 11-12, 2026 at the Lotte New York Palace in New York City. Inventiva leadership will also hold one-on-one meetings during the conference. | GlobeNewsWire | 2026-02-04 16:00:00 |
| Biotech Inventiva's 50% surge shows investor optimism over liver disease drug | A surge in Inventiva shares, up about 50% in the first few weeks of 2026, highlights investors' appetite for betting on the loss-making French biotech, which is on the verge of entering the fast-growing treatment market for liver disease MASH. | Reuters | 2026-01-28 10:39:54 |
| Are You Looking for a Top Momentum Pick? Why Inventiva S.A. | Does Inventiva S.A. Sponsored ADR (IVA) have what it takes to be a top stock pick for momentum investors? | Zacks Investment Research | 2026-01-26 13:00:28 |
| Inventiva S.A. (IVA) Presents at 44th Annual J.P. | Inventiva S.A. (IVA) Presents at 44th Annual J.P. | Seeking Alpha | 2026-01-15 14:16:01 |
| Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know | The consensus price target hints at a 200.6% upside potential for Inventiva (IVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. | Zacks Investment Research | 2026-01-08 10:56:07 |
| Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of “Moderate Buy” by Brokerages | Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven ratings firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy | Defense World | 2025-12-30 03:18:51 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-17 | 2026-02-17 | View Filing |
| 6-K | 2026-02-17 | 2026-02-17 | View Filing |
| SC 13G/A | 2026-02-13 | 2026-02-13 | View Filing |
| SC 13G | 2026-01-30 | 2026-01-30 | View Filing |
| 6-K | 2025-11-28 | 2025-11-28 | View Filing |
| 6-K | 2025-11-24 | 2025-11-21 | View Filing |
| SC 13D/A | 2025-11-19 | 2025-11-19 | View Filing |
| SC 13D/A | 2025-11-19 | 2025-11-19 | View Filing |
| 6-K | 2025-11-17 | 2025-11-17 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| SC 13G/A | 2025-11-14 | 2025-11-14 | View Filing |
| 6-K | 2025-11-13 | 2025-11-13 | View Filing |
| 424B5 | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G/A | 2025-11-13 | 2025-11-13 | View Filing |
| FWP | 2025-11-13 | 2025-11-13 | View Filing |
| FWP | 2025-11-12 | 2025-11-12 | View Filing |
| 424B5 | 2025-11-12 | 2025-11-12 | View Filing |
| 6-K | 2025-11-07 | 2025-11-07 | View Filing |
| 6-K | 2025-11-06 | 2025-11-06 | View Filing |
| 6-K | 2025-11-06 | 2025-11-06 | View Filing |
| 6-K | 2025-10-30 | 2025-10-30 | View Filing |
| SC 13D | 2025-10-21 | 2025-10-21 | View Filing |
| 6-K | 2025-10-20 | 2025-10-20 | View Filing |
| 6-K | 2025-10-14 | 2025-10-14 | View Filing |
| F-3 | 2025-10-14 | 2025-10-14 | View Filing |
| 6-K | 2025-10-01 | 2025-10-01 | View Filing |
| 6-K | 2025-09-29 | 2025-09-29 | View Filing |
| SC 13G/A | 2025-08-14 | 2025-08-14 | View Filing |
| SC 13G/A | 2025-07-31 | 2025-07-31 | View Filing |
| 6-K | 2025-07-29 | 2025-07-29 | View Filing |
| 6-K | 2025-07-09 | 2025-07-09 | View Filing |
| 6-K | 2025-07-07 | 2025-07-07 | View Filing |
| SC 13G | 2025-06-20 | 2025-06-20 | View Filing |
| 6-K | 2025-05-23 | 2025-05-23 | View Filing |
| 6-K | 2025-05-23 | 2025-05-23 | View Filing |
| 6-K | 2025-05-22 | 2025-05-22 | View Filing |
| SC 13G | 2025-05-15 | 2025-05-15 | View Filing |
| SC 13D/A | 2025-05-09 | 2025-05-09 | View Filing |
| SC 13D/A | 2025-05-07 | 2025-05-07 | View Filing |
| 6-K | 2025-05-05 | 2025-05-05 | View Filing |
| 6-K | 2025-05-02 | 2025-05-02 | View Filing |
| 6-K | 2025-04-30 | 2025-04-30 | View Filing |
| 6-K | 2025-04-30 | 2025-04-30 | View Filing |
| 6-K | 2025-04-24 | 2025-04-24 | View Filing |
| 20-F | 2025-04-15 | 2025-04-15 | View Filing |
| SC 13G | 2025-04-14 | 2025-04-14 | View Filing |
| 6-K | 2025-04-11 | 2025-04-11 | View Filing |
| 6-K | 2025-04-01 | 2025-04-01 | View Filing |
| SC 13G | 2025-03-31 | 2025-03-31 | View Filing |
| SC 13G | 2025-03-26 | 2025-03-26 | View Filing |
| 6-K | 2025-03-26 | 2025-03-26 | View Filing |
| 6-K | 2025-02-20 | 2025-02-20 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 6-K | 2025-02-10 | 2025-02-10 | View Filing |
| SC 13D/A | 2024-12-23 | 2024-12-23 | View Filing |
| 6-K | 2024-12-16 | 2024-12-16 | View Filing |
| 6-K | 2024-12-12 | 2024-12-12 | View Filing |
| 6-K | 2024-11-26 | 2024-11-26 | View Filing |
| 6-K | 2024-11-21 | 2024-11-21 | View Filing |
| 6-K | 2024-11-20 | 2024-11-20 | View Filing |
| 6-K | 2024-11-20 | 2024-11-20 | View Filing |
| 6-K | 2024-11-15 | 2024-11-15 | View Filing |
| 6-K | 2024-11-14 | 2024-11-14 | View Filing |
| SC 13G/A | 2024-11-13 | 2024-11-13 | View Filing |
| 6-K | 2024-11-04 | 2024-11-04 | View Filing |
| 6-K | 2024-10-30 | 2024-10-30 | View Filing |
| SC 13D/A | 2024-10-21 | 2024-10-21 | View Filing |
| SC 13D/A | 2024-10-21 | 2024-10-21 | View Filing |
| 6-K | 2024-10-15 | 2024-10-15 | View Filing |
| 6-K | 2024-10-15 | 2024-10-15 | View Filing |
| 6-K | 2024-09-25 | 2024-09-25 | View Filing |
| 6-K | 2024-07-31 | 2024-07-31 | View Filing |
| SC 13D/A | 2024-07-19 | 2024-07-19 | View Filing |
| 6-K | 2024-07-18 | 2024-07-18 | View Filing |
| 6-K | 2024-07-05 | 2024-07-05 | View Filing |
| 6-K | 2024-06-21 | 2024-06-21 | View Filing |
| 6-K | 2024-06-21 | 2024-06-21 | View Filing |
| 6-K | 2024-06-05 | 2024-06-05 | View Filing |
| 6-K | 2024-05-30 | 2024-05-30 | View Filing |
| 6-K | 2024-05-30 | 2024-05-30 | View Filing |
| 6-K | 2024-05-21 | 2024-05-21 | View Filing |
| 6-K | 2024-05-16 | 2024-05-16 | View Filing |
| 6-K | 2024-05-13 | 2024-05-13 | View Filing |
| 6-K | 2024-05-13 | 2024-05-13 | View Filing |
| SC 13D/A | 2024-05-03 | 2024-05-03 | View Filing |
| 20-F | 2024-04-03 | 2024-04-03 | View Filing |
| 6-K | 2024-03-27 | 2024-03-27 | View Filing |
| 6-K | 2024-03-18 | 2024-03-18 | View Filing |
| 6-K | 2024-03-07 | 2024-03-07 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Adaptive Wave | 32.38% | 0.75 | 2 | 0.56 | 0.56 | 23.43 |
| Bull Bias | 23.96% | 1.07 | 39 | 0.75 | 0.56 | 15.01 |
| VWAP | 21.57% | 0.98 | 39 | 0.59 | 0.38 | 12.62 |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxx |
| xxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxx | xxxx | xxxx |
| xxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxx |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |